Phase 1 Unit
“Success in the first battle is equal to half the victory”
– Chinese proverb
China has stepped up investment in drug innovation in recent years, both in basic research and in industry research and development. Some of the leading Chinese pharmaceuticals that previously focused on generics have started building capabilities and making investments in innovative drugs. Furthermore, there is a large group of innovative biotech companies – driven mainly by US-returnees – that are working on new therapies to address global unmet medical needs.
At the same time, the NMPA has taken steps to attract more foreign R&D to China which has led to an influx of foreign companies that are approaching China earlier than ever before.
With an increase in domestic innovation and more interest in early stage development from abroad, CSC has established a Phase I Unit, in collaboration with Weifang 2nd People’ s Hospital of Shandong Province, in a conscious effort to bring our unique quality and service standards to early stage clinical trials.
How we can help:
- Phase I Clinical Trials
- Single Dose Escalation Studies
- Multiple Dose Escalation Studies
- Medical Device and Drug Treatment Safety Studies
- Innovative Drug Trials
- PD/PK Studies
- PoC Trials
- Bioequivalence Studies
- Healthy Volunteers
- Study Patients
More About the Clinical Service Center CRO
OUR LEADERSHIP TEAM
Our senior managers and executives were trained in the West, have worked for big Western pharmaceutical companies, and are committed to bringing the best clinical practices to China.
For more than a decade, Clinical Service Center-“CSC” (formerly Beijing Clinical Service Center – “BCSC”) has been conducting top-quality clinical trial services in China for pharmaceutical, biotech, and medical device companies the world over.
FULL SERVICE PLUS
At CSC we define our business scope as “full-service plus” because we go above and beyond the requirements of a traditional full-service CRO to provide you with the end-to-end services you require to get your product in to the China market.